The role of molecular mimicry in the etiology of Guillain Barré Syndrome
-
Published:2011-05
Issue:
Volume:56
Page:3-12
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Grozdanova Aleksandra,Apostolski Slobodan,Suturkova Ljubica
Abstract
Molecular mimicry between host tissue structures and microbial components has been proposed as the pathogenic mechanism for triggering of autoimmune diseases by preceding infection. Recent studies stated that molecular mimicry as the causative mechanism remains unproven for most of the human diseases. Still, in the case of the peripheral neuropathy Guillain-Barré syndrome (GBS) this hypothesis is supported by abundant experimental evidence. GBS is the most frequent cause of acute neuromuscular paralysis and in some cases occurs after infection with Campylobacter jejuni (C. jejuni). Epidemiological studies, showed that more than one third of GBS patients had antecedent C. jejuni infection and that only specific C. jejuni serotypes are associated with development of GBS. The molecular mimicry between the human gangliosides and the core oligosaccharides of bacterial lipopolysaccharides (LPSs) presumably results in production of antiganglioside cross-reactive antibodies which are likely to be a contributory factor in the induction and pathogenesis of GBS. Antiganglioside antibodies were found in the sera from patients with GBS and by sensitization of rabbits with gangliosides and C. jejuni LPSs animal disease models of GBS were established. GBS as prototype of post-infection immune-mediated disease probably will provide the first verification that an autoimmune disease can be triggered by molecular mimicry.
Publisher
Macedonian Pharmaceutical Association
Reference58 articles.
1. Albert, L.J., Inman, R.D., 1999. Molecular mimicry and autoimmunity. N. Engl. J. Med. 341, 2068–2074. 2. Ang, C.W., De Klerk, M.A., Endtz, H.P., Jacobs, B.C., Laman, J. D., Van der Meche, F.G.A., Van Doorn, P.A., 2001. GuillainBarre syndrome and Miller-Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect. Immun. 69, 2462–2469. 3. Ang, C.W., Laman, J.D., Willison, H.J., Wagner, E.R., Endtz, H.P., De Klerk, M.A., Tio-Gillen, A.P., Van den Braak, N., Jacobs, B.C., Van Doorn, P.A., 2002. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infect. Immun. 70, 1202-1208. 4. Ang, C.W., Jacobs, B.C., Laman, J.D., 2004. The GuillainBarre syndrome: a true case of molecular mimicry. Trends Immunol. 25, 61–66. 5. Ariga, T., Yu, R.K., 2005. Anti-glycolipid antibodies in GuillainBarre syndrome and related diseases: review of clinical features and antibody specificities. J. Neurosci. Res. 80, 1–17.
|
|